SG10201506761XA - Deuterated analogs of pridopidine useful as dopaminergic stabilizers - Google Patents
Deuterated analogs of pridopidine useful as dopaminergic stabilizersInfo
- Publication number
- SG10201506761XA SG10201506761XA SG10201506761XA SG10201506761XA SG10201506761XA SG 10201506761X A SG10201506761X A SG 10201506761XA SG 10201506761X A SG10201506761X A SG 10201506761XA SG 10201506761X A SG10201506761X A SG 10201506761XA SG 10201506761X A SG10201506761X A SG 10201506761XA
- Authority
- SG
- Singapore
- Prior art keywords
- pridopidine
- useful
- deuterated analogs
- dopaminergic stabilizers
- dopaminergic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201070385 | 2010-09-03 | ||
| US38085110P | 2010-09-08 | 2010-09-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201506761XA true SG10201506761XA (en) | 2015-10-29 |
Family
ID=44653278
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013014022A SG188298A1 (en) | 2010-09-03 | 2011-08-31 | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| SG10201506761XA SG10201506761XA (en) | 2010-09-03 | 2011-08-31 | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013014022A SG188298A1 (en) | 2010-09-03 | 2011-08-31 | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US20130197031A1 (de) |
| EP (1) | EP2611759A1 (de) |
| JP (1) | JP2013536825A (de) |
| KR (1) | KR20140008297A (de) |
| CN (1) | CN103249697B (de) |
| AU (2) | AU2011298382A1 (de) |
| BR (1) | BR112013005125A2 (de) |
| CA (1) | CA2810092A1 (de) |
| CL (1) | CL2013000604A1 (de) |
| EA (1) | EA201390332A1 (de) |
| IL (1) | IL224776A (de) |
| MX (1) | MX2013002453A (de) |
| NZ (1) | NZ608120A (de) |
| PE (1) | PE20140105A1 (de) |
| SG (2) | SG188298A1 (de) |
| WO (1) | WO2012028635A1 (de) |
| ZA (1) | ZA201301902B (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| PL2146961T3 (pl) * | 2007-04-12 | 2014-09-30 | Teva Pharmaceuticals Int Gmbh | Pochodne N-tlenkowe i/lub Di-N-tlenkowe stabilizatorów/modulatorów receptora dopaminowego, wykazujące udoskonalone profile efektów ubocznych |
| EA201390332A1 (ru) | 2010-09-03 | 2013-08-30 | Ивакс Интернэшнл Гмбх | Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов |
| CN103958469B (zh) | 2011-09-07 | 2016-04-20 | 梯瓦制药国际有限责任公司 | 一种新的普利多匹定盐酸盐多晶型形态 |
| EP2787997A4 (de) | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | Hydrobromidsalz von pridopidin |
| MX2014011971A (es) | 2012-04-04 | 2015-01-16 | Ivax Int Gmbh | Composiciones farmaceuticas para terapia de combinacion. |
| EP4345100A3 (de) | 2012-09-18 | 2024-04-10 | Auspex Pharmaceuticals, Inc. | Formulierungen mit pharmakokinetik von deuterierten benzochinolininhibitoren von vesikulärem monoamintransporter 2 |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| PL3010506T3 (pl) | 2013-06-21 | 2021-11-02 | Prilenia Neurotherapeutics Ltd. | Pridopidyna w leczeniu choroby huntingtona |
| US10166183B2 (en) | 2014-02-07 | 2019-01-01 | Auspex Pharmaceuticals, Inc. | Pharmaceutical formulations |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| MX2017008136A (es) | 2014-12-22 | 2018-03-06 | Teva Pharmaceuticals Int Gmbh | Sal de l-tartrato de pridopidina. |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| DK3261721T3 (da) | 2015-02-25 | 2022-11-28 | Prilenia Neurotherapeutics Ltd | Anvendelse af pridopidin til forbedring af hukommelse |
| EA201791977A1 (ru) * | 2015-03-06 | 2018-01-31 | Оспекс Фармасьютикалз, Инк. | Способы лечения патологических непроизвольных движений |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| AU2017223838B2 (en) | 2016-02-24 | 2022-09-29 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| CA3035099C (en) | 2016-08-24 | 2023-01-17 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating dystonias |
| CA3035092C (en) | 2016-08-24 | 2022-05-31 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating functional decline |
| EP3512517A4 (de) | 2016-09-15 | 2020-05-06 | Prilenia Neurotherapeutics Ltd. | Verwendung von pridopidin zur behandlung von angst und depression |
| JP6977029B2 (ja) | 2016-09-16 | 2021-12-08 | プリレニア ニューロセラピューティクス リミテッド | レット症候群を治療するためのプリドピジンの使用 |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| DK3570940T3 (da) | 2017-01-20 | 2024-02-19 | Prilenia Neurotherapeutics Ltd | Pridopidin til anvendelse i behandling af fragilt x-syndrom |
| US10459055B2 (en) * | 2017-04-07 | 2019-10-29 | Case Western Reserve University | System and method for reduced field of view MR fingerprinting for parametric mapping |
| HUE061505T2 (hu) | 2017-08-14 | 2023-07-28 | Prilenia Neurotherapeutics Ltd | Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel |
| EA202090542A1 (ru) | 2017-08-30 | 2020-06-08 | Приления Ньюротерапьютикс Лтд. | Высококонцентрированные лекарственные формы придопидина |
| CN111343982A (zh) | 2017-09-08 | 2020-06-26 | 普瑞尼亚神经治疗有限公司 | 用于治疗药物诱发的异动症的普利多匹定 |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| EP4146208A4 (de) | 2020-05-04 | 2024-05-22 | Prilenia Neurotherapeutics Ltd. | Behandlung von virusinfektionen, erkrankungen oder störungen unter verwendung eines selektiven s1r-agonisten |
| KR20230028244A (ko) * | 2020-05-20 | 2023-02-28 | 썰테고 테라퓨틱스 아이엔씨. | 고리 중수소화 가복사돌 및 정신 장애의 치료를 위한 이의 용도 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| EP1104760B1 (de) * | 1999-12-03 | 2003-03-12 | Pfizer Products Inc. | Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel |
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| SE9904724D0 (sv) * | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| SE9904723D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
| DE10123129A1 (de) * | 2001-05-02 | 2002-11-14 | Berolina Drug Dev Ab Svedala | Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| US7004629B2 (en) | 2003-07-26 | 2006-02-28 | Arthur Joseph Shrader | Method and apparatus for hanging a resealable bag |
| CA2569843A1 (en) | 2004-06-08 | 2005-12-22 | A. Carlsson Research Ab | New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission |
| DK1802573T3 (en) | 2004-10-13 | 2016-12-19 | Teva Pharmaceuticals Int Gmbh | METHOD OF SYNTHESIS OF 4- (3-METHANSULPHONYLPHENYL) -1-N-PROPYL-PIPERIDINE. |
| CA2624179A1 (en) * | 2005-10-06 | 2007-04-12 | Auspex Pharmaceuticals, Inc. | Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties |
| SE529246C2 (sv) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| WO2007058998A2 (en) | 2005-11-14 | 2007-05-24 | Auspex Pharmaceuticals, Inc. | Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties |
| CN101360742A (zh) * | 2005-11-14 | 2009-02-04 | 奥斯拜客斯制药有限公司 | 具有血清素源性活性和增强的治疗特性的取代苯基哌啶 |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| PL2146961T3 (pl) | 2007-04-12 | 2014-09-30 | Teva Pharmaceuticals Int Gmbh | Pochodne N-tlenkowe i/lub Di-N-tlenkowe stabilizatorów/modulatorów receptora dopaminowego, wykazujące udoskonalone profile efektów ubocznych |
| CN101765428A (zh) * | 2007-06-18 | 2010-06-30 | A·卡尔森研究股份有限公司 | 多巴胺稳定剂的用途 |
| US8288414B2 (en) * | 2007-09-12 | 2012-10-16 | Deuteria Pharmaceuticals, Inc. | Deuterium-enriched lenalidomide |
| US20110206782A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| EA201390332A1 (ru) | 2010-09-03 | 2013-08-30 | Ивакс Интернэшнл Гмбх | Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов |
| CN103958469B (zh) | 2011-09-07 | 2016-04-20 | 梯瓦制药国际有限责任公司 | 一种新的普利多匹定盐酸盐多晶型形态 |
| EP2787997A4 (de) | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | Hydrobromidsalz von pridopidin |
| MX2014011971A (es) | 2012-04-04 | 2015-01-16 | Ivax Int Gmbh | Composiciones farmaceuticas para terapia de combinacion. |
| EP2900330A4 (de) | 2012-09-27 | 2016-05-25 | Teva Pharma | Laquinimod und pridopidin zur behandlung von neurodegenerativen erkrankungen |
| MX2015003812A (es) | 2012-09-27 | 2015-07-17 | Teva Pharma | Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington. |
| PL3010506T3 (pl) | 2013-06-21 | 2021-11-02 | Prilenia Neurotherapeutics Ltd. | Pridopidyna w leczeniu choroby huntingtona |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| HUE058288T2 (hu) | 2014-01-22 | 2022-07-28 | Prilenia Neurotherapeutics Ltd | Pridopidin módosított hatóanyag-leadású készítményei |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| MX2017008136A (es) | 2014-12-22 | 2018-03-06 | Teva Pharmaceuticals Int Gmbh | Sal de l-tartrato de pridopidina. |
| DK3261721T3 (da) | 2015-02-25 | 2022-11-28 | Prilenia Neurotherapeutics Ltd | Anvendelse af pridopidin til forbedring af hukommelse |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| WO2017015615A1 (en) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| WO2017015515A1 (en) | 2015-07-23 | 2017-01-26 | Knowles Electronics, Llc | Microphone with temperature sensor |
| AU2017223838B2 (en) | 2016-02-24 | 2022-09-29 | Prilenia Neurotherapeutics Ltd. | Treatment of neurodegenerative eye disease using pridopidine |
| CA3035099C (en) | 2016-08-24 | 2023-01-17 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating dystonias |
| CA3035092C (en) | 2016-08-24 | 2022-05-31 | Prilenia Therapeutics Development Ltd. | Use of pridopidine for treating functional decline |
| EP3512517A4 (de) | 2016-09-15 | 2020-05-06 | Prilenia Neurotherapeutics Ltd. | Verwendung von pridopidin zur behandlung von angst und depression |
| WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
| WO2018053230A1 (en) | 2016-09-16 | 2018-03-22 | Cargill, Incorporated | Genetically modified lactate-consuming yeasts and fermentation processes using such genetically modified yeasts |
| DK3570940T3 (da) | 2017-01-20 | 2024-02-19 | Prilenia Neurotherapeutics Ltd | Pridopidin til anvendelse i behandling af fragilt x-syndrom |
| HUE061505T2 (hu) | 2017-08-14 | 2023-07-28 | Prilenia Neurotherapeutics Ltd | Módszer amyothrophiás lateralsclerosis kezelésére pridopidinnel |
| NL2019473B1 (en) | 2017-09-01 | 2019-03-11 | Isobionics B V | Terpene Synthase producing patchoulol and elemol, and preferably also pogostol |
| CN111343982A (zh) | 2017-09-08 | 2020-06-26 | 普瑞尼亚神经治疗有限公司 | 用于治疗药物诱发的异动症的普利多匹定 |
-
2011
- 2011-08-31 EA EA201390332A patent/EA201390332A1/ru unknown
- 2011-08-31 WO PCT/EP2011/064954 patent/WO2012028635A1/en active Application Filing
- 2011-08-31 MX MX2013002453A patent/MX2013002453A/es active IP Right Grant
- 2011-08-31 JP JP2013526452A patent/JP2013536825A/ja active Pending
- 2011-08-31 SG SG2013014022A patent/SG188298A1/en unknown
- 2011-08-31 KR KR20137007971A patent/KR20140008297A/ko not_active Application Discontinuation
- 2011-08-31 CN CN201180042460.5A patent/CN103249697B/zh active Active
- 2011-08-31 NZ NZ60812011A patent/NZ608120A/en not_active IP Right Cessation
- 2011-08-31 AU AU2011298382A patent/AU2011298382A1/en not_active Abandoned
- 2011-08-31 SG SG10201506761XA patent/SG10201506761XA/en unknown
- 2011-08-31 PE PE2013000359A patent/PE20140105A1/es not_active Application Discontinuation
- 2011-08-31 BR BR112013005125A patent/BR112013005125A2/pt not_active IP Right Cessation
- 2011-08-31 CA CA 2810092 patent/CA2810092A1/en not_active Abandoned
- 2011-08-31 US US13/820,024 patent/US20130197031A1/en not_active Abandoned
- 2011-08-31 EP EP20110757801 patent/EP2611759A1/de not_active Withdrawn
-
2013
- 2013-02-18 IL IL224776A patent/IL224776A/en not_active IP Right Cessation
- 2013-03-01 CL CL2013000604A patent/CL2013000604A1/es unknown
- 2013-03-13 ZA ZA2013/01902A patent/ZA201301902B/en unknown
-
2015
- 2015-12-14 US US14/968,510 patent/US20160095847A1/en not_active Abandoned
- 2015-12-14 US US14/968,522 patent/US20160166559A1/en not_active Abandoned
-
2016
- 2016-10-26 AU AU2016250390A patent/AU2016250390A1/en not_active Abandoned
-
2018
- 2018-04-23 US US15/960,041 patent/US20180235950A1/en not_active Abandoned
- 2018-09-17 US US16/133,192 patent/US10799492B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013536825A (ja) | 2013-09-26 |
| US10799492B2 (en) | 2020-10-13 |
| AU2011298382A1 (en) | 2013-05-02 |
| BR112013005125A2 (pt) | 2016-08-16 |
| IL224776A (en) | 2017-07-31 |
| ZA201301902B (en) | 2014-05-28 |
| CL2013000604A1 (es) | 2013-11-15 |
| PE20140105A1 (es) | 2014-02-14 |
| CN103249697A (zh) | 2013-08-14 |
| EP2611759A1 (de) | 2013-07-10 |
| CN103249697B (zh) | 2016-06-15 |
| MX2013002453A (es) | 2013-08-01 |
| US20190015401A1 (en) | 2019-01-17 |
| NZ608120A (en) | 2014-12-24 |
| EA201390332A1 (ru) | 2013-08-30 |
| WO2012028635A1 (en) | 2012-03-08 |
| US20160166559A1 (en) | 2016-06-16 |
| US20180235950A1 (en) | 2018-08-23 |
| SG188298A1 (en) | 2013-04-30 |
| US20130197031A1 (en) | 2013-08-01 |
| AU2016250390A1 (en) | 2016-11-10 |
| CA2810092A1 (en) | 2012-03-08 |
| KR20140008297A (ko) | 2014-01-21 |
| US20160095847A1 (en) | 2016-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201301902B (en) | Deuterated analogs of pridopidine useful as dopaminergic stabilizers | |
| HK1244183A1 (zh) | Ivacaftor的氘化衍生物 | |
| HK1216254A1 (zh) | 取代的核苷酸類似物 | |
| EP2655392A4 (de) | Zyklische nukleotidanaloge | |
| HUE047354T2 (hu) | Ivacaftor deuterizált származékai | |
| EP2536276A4 (de) | Neue bexarotenanaloga | |
| IL227754B (en) | Analogues of 4-hydroxybutyric acid with deuterium | |
| ZA201309245B (en) | Novel fluoroergoline analogs | |
| IL225617A0 (en) | Compounds that are similar to cyclosporine | |
| HK1184394A1 (en) | Use of glutamide stabilizers | |
| GB201311220D0 (en) | Improved structure of shoe | |
| IL225616A0 (en) | Compounds that are similar to cyclosporine | |
| ZA201404034B (en) | Anhydrous antiperspirant compositions | |
| HK1203355A1 (en) | Uses of 4-desferrithiocin analogs 4- | |
| TWM388611U (en) | Improved structure of light-emitting device | |
| IL228985A0 (en) | Diazonamide analogs | |
| HK1160777A1 (en) | Novel use of neohesperidoside | |
| TWM400766U (en) | Improved structure of insole | |
| TWM387196U (en) | Improved structure of LED | |
| TWM402983U (en) | Improved structure of LED | |
| TWM390954U (en) | Structure of light-emitting yarn | |
| TWM401317U (en) | Improved multi-weave structure of socks | |
| TWM400768U (en) | High heel structure | |
| TWM400763U (en) | Improved structure of cold-accumulating cravats | |
| TWM388315U (en) | Improved structure of hemoclip |